Back to Newsroom
Back to Newsroom

Lawsuits Filed Against RCL, LVS and ICPT - Jakubowitz Law Pursues Shareholders Claims

Monday, 07 December 2020 06:20 AM

Jakubowitz Law

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / December 7, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Royal Caribbean Cruises Ltd. (NYSE:RCL)

CONTACT JAKUBOWITZ ABOUT RCL:
https://claimyourloss.com/securities/royal-caribbean-cruises-ltd-loss-submission-form/?id=11388&from=1

Class Period : February 4, 2020 - March 17, 2020

Lead Plaintiff Deadline : December 7, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.

Las Vegas Sands Corp. (NYSE:LVS)

CONTACT JAKUBOWITZ ABOUT LVS:
https://claimyourloss.com/securities/las-vegas-sands-corp-loss-submission-form/?id=11388&from=1

Class Period : February 27, 2016 - September 15, 2020

Lead Plaintiff Deadline : December 21, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

CONTACT JAKUBOWITZ ABOUT ICPT:
https://claimyourloss.com/securities/intercept-pharmaceuticals-inc-loss-submission-form/?id=11388&from=1

Class Period : September 28, 2019 - October 7, 2020

Lead Plaintiff Deadline : January 4, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: